Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Cystic Fibrosis Drug Sales Should Soar; VX-661/Ivacaftor To Lead Way

Executive Summary

Sales of key cystic fibrosis drugs will jump in western economies over the next decade, driven by strong uptake of high-cost CFTR modulator therapies and longer use as life expectancies improve, according to a new report by Datamonitor Healthcare.

Advertisement

Related Content

Vertex Plays Defense In CF With Concert Deal
PTC Tumbles On Ataluren Failure In Cystic Fibrosis
Keeping Track: Submissions For Dupilumab, Nusinersen; AbbVie Finds Breakthrough Space In Hep C
Vertex's VX-661 Has Positive Outlook Despite Futility Finding
Why Pricing Orkambi Below Kalydeco Is A Savvy Strategy For Vertex
Vertex’s Orkambi Approved With Broad Label For Cystic Fibrosis
Vertex Gets Quick FDA Approval Of Kalydeco; Prices New CF Drug At $294,000 Per Year

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097383

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst

Cancel